Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for an adaptive Phase 2/3 trial with the potential to serve as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 1, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Barclays Global Healthcare Conference 2019 – Miami , March 12-14, 2019 March 12 , 4:20 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Feb. 7, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being
View HTML
Toggle Summary Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 17, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018 , the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 27, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018 .
View HTML